Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of remetinostat for the treatment of early-stage cutaneous T-cell lymphoma

Next Previous
Trial Profile

A phase III trial of remetinostat for the treatment of early-stage cutaneous T-cell lymphoma

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 11 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remetinostat (Primary)
  • Indications Cutaneous T-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Medivir AB

    • Most Recent Events

    • 05 May 2020 According to a Medivir AB media release, the company has determined the design of a phase III study and is searching a partner for the continued development and commercialization of remetinostat.
    • 14 Feb 2019 According to a Medivir AB media release, after having clarifying and positive discussions with the FDA regarding the design of the phase III, company is now further developing the phase III design based on the clarifications from the FDA.
    • 18 Jun 2018 According to a Medivir AB media release, the company decided to continue the discussions with the US Food and Drug Administration (FDA) to agree on the design and start of the study will not be possible earlier than 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top